How this instrument works
Prostate specific antigen is produced by prostate tissue generally, cancerous or not, so a larger gland tends to release more of it into the bloodstream regardless of what's actually growing inside it. Benign prostatic hyperplasia — a common, non-cancerous enlargement that becomes more likely with age — can push PSA up on its own, which makes a raw PSA reading a blunt instrument: the same number might mean very different things in a small gland versus a large one.
PSA density divides the measured PSA by the prostate's volume in cubic centimetres, obtained from a transrectal ultrasound or MRI scan (volume is typically estimated with the ellipsoid formula: height × width × length × 0.523). Benson and colleagues introduced the measure in 1992, reasoning that expressing PSA per unit of gland tissue would separate a genuinely worrying signal from one that's simply proportional to size. A density around 0.15 ng/mL/cc became the figure most commonly cited as a threshold worth a closer look, though it was never meant as a strict line — more recent literature narrows or shifts that number somewhat, often landing in a 0.10-0.15 range depending on factors like whether a patient has already had a negative biopsy.
The measure inherits the imprecision of whatever volume estimate feeds it — ultrasound and MRI can disagree on the same gland by a meaningful margin, and the ellipsoid formula is itself an approximation of an irregular shape. In practice, density is one input among several — PSA velocity over time, the free-to-total PSA ratio, and increasingly prostate MRI findings — that urologists weigh together rather than any single ratio decided alone.
- Enter Serum PSA in ng/mL from a recent blood test.
- Enter Prostate volume in cc, as measured by ultrasound or MRI.
- Read PSA density in ng/mL per cc, and weigh it against the roughly 0.10-0.15 range clinicians commonly reference.
Worked example — same-ish PSA, different gland sizes
A PSA of 6 ng/mL in a 40 cc prostate: 6 ÷ 40 = 0.15 ng/mL/cc, right at the figure most often cited as worth a closer look.
Now compare a PSA of 8 ng/mL in a smaller, 25 cc gland: 8 ÷ 25 = 0.32 ng/mL/cc — more than double the density, despite a PSA only a third higher, because so much less tissue is producing it. And a PSA of 4 ng/mL in a considerably larger 60 cc gland comes out to 4 ÷ 60 ≈ 0.067 ng/mL/cc — a low, reassuring figure the raw PSA number alone would never have suggested.
Questions
Why divide PSA by prostate volume at all?
Because benign enlargement alone raises PSA, so a raw reading can't distinguish a big, harmless gland from a smaller one with something concerning growing inside it. Dividing by the actual measured volume adjusts for gland size, giving a figure that reflects how much PSA each cubic centimetre of tissue is producing rather than the total output of an unusually large organ.
What counts as a high PSA density?
Roughly 0.15 ng/mL/cc has historically been the most commonly cited figure worth a closer look, though it was never a strict pass-fail line. More recent studies use a somewhat narrower band, often 0.10-0.15 ng/mL/cc, with the exact cutoff shifting depending on factors like age, PSA range, and whether the patient has already had a negative prior biopsy.
How is prostate volume actually measured?
Via transrectal ultrasound or MRI, using three dimensions of the gland — height, width, and length — plugged into the ellipsoid formula (their product times 0.523) to approximate volume. Ultrasound and MRI can produce somewhat different volume estimates for the same gland, which carries through as uncertainty in the resulting density figure.
Is 0.15 ng/mL/cc a hard threshold for ordering a biopsy?
No — it's a commonly cited reference point, not a fixed rule. Clinicians weigh density alongside PSA trends over time, age, family history, digital rectal exam findings, and increasingly MRI results before deciding whether a biopsy is warranted, rather than acting on one ratio in isolation.
What causes a prostate to enlarge without cancer?
Benign prostatic hyperplasia, an extremely common, age-related, non-cancerous growth of prostate tissue that can start as early as a man's forties and becomes more prevalent with age. It raises PSA simply because there's more glandular tissue producing it, entirely separate from any malignant process.
How does PSA density compare to other PSA-based measures?
PSA velocity tracks how fast PSA is rising over repeated tests, and the free-to-total PSA ratio looks at what fraction circulates unbound — both capture information density doesn't. Density's advantage is that it only needs one blood draw plus a volume measurement already often available from imaging, but it works best combined with these other measures rather than used alone.
References
- Benson MC et al. 1992, J Urol — original study (DOI)
- Nature Scientific Reports 2020 — PSA density predicting clinically significant prostate cancer
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.